Indeed, increasing evidence suggests that Mcl-1 is important in melanoma (Sale et al., 2019), hepatocellular carcinoma (Sieghart et al., 2006), breast cancer (Campbell et al., 2018), and various hematological malignancies (Wei et al., 2020). Here, MCL1 is linked to breast carcinoma.